Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Even H Rustad

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Best Practice & Research. Clinical Haematology|March 7, 2020
Monitoring minimal residual disease in the bone marrow using next generation sequencingEven H Rustad, Eileen M Boyle
Best Practice & Research. Clinical Haematology|March 7, 2020
Genomic profiling of multiple myeloma: New insights and modern technologiesMalin Hultcrantz, Venkata Yellapantula, Even H Rustad
Best Practice & Research. Clinical Haematology|March 7, 2020
Reconstructing the evolutionary history of multiple myelomaFrancesco Maura, Even H Rustad, Eileen M Boyle, et al.
JAMA Oncology|December 13, 2019
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A ReviewFrancesco Maura, Niccolò Bolli, Even H Rustad, et al.
Communications Biology|March 30, 2021
mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignanciesEven H Rustad, Ferran Nadeu, Nicos Angelopoulos, et al.
Plos One|March 23, 2019
Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myelomaEven H Rustad, Malin Hultcrantz, Venkata D Yellapantula, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2020
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation SequencingMattia D'Agostino, Gian Maria Zaccaria, Bachisio Ziccheddu, et al.
Nature Communications|August 28, 2021
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myelomaKylee H Maclachlan, Even H Rustad, Andriy Derkach, et al.
Seminars in Cell & Developmental Biology|May 7, 2021
Chromothripsis as a pathogenic driver of multiple myelomaFrancesco Maura, Eileen M Boyle, Even H Rustad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple MyelomaMalin Hultcrantz, Even H Rustad, Venkata Yellapantula, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Best Practice & Research. Clinical Haematology|March 7, 2020
Monitoring minimal residual disease in the bone marrow using next generation sequencingEven H Rustad, Eileen M Boyle
Best Practice & Research. Clinical Haematology|March 7, 2020
Genomic profiling of multiple myeloma: New insights and modern technologiesMalin Hultcrantz, Venkata Yellapantula, Even H Rustad
Best Practice & Research. Clinical Haematology|March 7, 2020
Reconstructing the evolutionary history of multiple myelomaFrancesco Maura, Even H Rustad, Eileen M Boyle, et al.
JAMA Oncology|December 13, 2019
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A ReviewFrancesco Maura, Niccolò Bolli, Even H Rustad, et al.
Communications Biology|March 30, 2021
mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignanciesEven H Rustad, Ferran Nadeu, Nicos Angelopoulos, et al.
Plos One|March 23, 2019
Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myelomaEven H Rustad, Malin Hultcrantz, Venkata D Yellapantula, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2020
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation SequencingMattia D'Agostino, Gian Maria Zaccaria, Bachisio Ziccheddu, et al.
Nature Communications|August 28, 2021
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myelomaKylee H Maclachlan, Even H Rustad, Andriy Derkach, et al.
Seminars in Cell & Developmental Biology|May 7, 2021
Chromothripsis as a pathogenic driver of multiple myelomaFrancesco Maura, Eileen M Boyle, Even H Rustad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple MyelomaMalin Hultcrantz, Even H Rustad, Venkata Yellapantula, et al.
Pageof 3